Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 21 November, 2024

John Carroll talks to industry execs about the FDA, the new guard, funding and more — how are they planning for 2025? Tune in — register today.

presented by Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

news Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B Amgen names Stanford geneticist and biotech founder to CSO post Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

Dec 03 12:30pm ET From AI to IRA to GLP-1s: Unpacking the major healthcare trends at #JPM2025 sponsored by Real Chemistry Dec 04 12:00pm ET The pragmatic shift: Designing trials that fit the real world sponsored by Flatiron Dec 09 1:00pm ET Accelerating drug discovery with an end-to-end imaging data management platform sponsored by Flywheel Dec 12 11:00am ET Accelerating discovery in targeted protein degradation: Innovative approaches to degrader screening sponsored by Bio Techne

Biopharma’s elite are descending upon JPM, and our event is your insider’s guide to the industry. Join conversations with dealmakers, investors, and industry titans. The Endpoints Hub is your oasis amidst the JPM frenzy. Secure your spot now — Early Bird is ending soon.

endpoints pharma NewAmsterdam aces Phase 3 trial, but investors are skeptical When generative AI meets the FDA: First digital health adcomm kicks off discussion FDA updates label of 33-year-old cancer drug with new dose and warning Venrock adds $500M to healthcare investing strategy after outlining 10th fund in January

in case you missed it 1. Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra 2. Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy 3. Updated: Sage reports Phase 2 failure in Huntington's disease, ends drug's development 4. Pfizer taps oncology head Boshoff as Dolsten's chief scientific officer successor 5. Exclusive: Former Pfizer commercial chief Angela Hwang to join Flagship 6. Pfizer partners with two more Flagship biotechs on obesity, cancer 7. 23andMe inks new research partnership as it winds down internal drug development efforts